Efficacy and tolerability of lapatinib in the management of breast cancer

Breast Cancer: Basic and Clinical Research

Volumn 6, Issue 1, 2012, Pages 67-77

  Rana, Punam ^a   Sridhar, Srikala S ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Breast cancer; Efficacy; Lapatinib; Tolerability

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; GEMCITABINE; LAPATINIB; LETROZOLE; NAVELBINE; NERATINIB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARDIOTOXICITY; CELL GROWTH; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM METASTASIS; COMMON COLD SYMPTOM; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; INFECTION; LIVER FUNCTION TEST; LIVER TOXICITY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE DRUG DOSE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; TREATMENT DURATION; VOMITING;

EID: 84859463502     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/BCBCR.S6374     Document Type: Review

References (55)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. American Cancer Society, Facts and Figures, 2010. [http://www.can-cer.org/Cancer/BreastCancer/OverviewGuide/breast-cancer-overview-survival-rates].
3. Slamon DJ, Clark GM, Wong SG, etal. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
4. Slamon DJ, Godolphin W, Jones LA, etal. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905): 707-12.
5. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu-oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. JCO. 1993;11(10):1936-42.
6. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. JCO. 1989;7(8):1120-8.
7. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37.
8. Olayioye MA, Graus-Porta D, Beerli RR, et al. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol. 1998;18(9):5042-51.
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. NEJM. 2001;344(11):783-92.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM. 2005; 353(16):1659-72.
11. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemo-therapy for operable HER2-positive breast cancer. NEJM. 2005;353(16): 1673-84.
12. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. NEJM. 2011;365(14):1273-83.
13. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. NEJM. 2006; 354(8):809-20.
14. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. JNCI. 2007;99(8):628-38.
15. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):215.
16. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117-27.
17. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. MCT. 2002;1(9):707-17.
18. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21(41): 6255-63.
19. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;64(18):6652-9.
20. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. MCT. 2001;1(2):85-94.
21. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. MCT. 2007;6(2):667-74.
22. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630-9.
23. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. PNAS. 2006;103(20):7795-800.
24. Trowe T, Boukouvala S, Calkins K, et al. EXEL-7647inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res. 2008;14(8):2465-75.
25. Kataoka Y, Mukohara T, Shimada H, et al. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol. 2010;21(2): 255-62.
26. Bence AK, Anderson EB, Halepota MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2inhibitor, in healthy subjects. Invest New Drugs. 2005;23(1): 39-49.
27. Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. JCO. 2005;23(23): 5305-13.
28. Spector NL, Xia W, Burris H III, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. JCO. 2005;23(11):2502-12.
29. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008;19(6):1068-74.
30. Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first-or second-line trastuzumab-containing regimens. Ann Oncol. 2009;20(6):1026-31.
31. Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. JCO. 2008;26(34):5544-52.
32. Chu QS, Schwartz G, de Bono J, et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. JCO. 2007;25(24):3753-8.
33. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. NEJM. 2006;355(26):2733-43.
34. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3): 533-43.
35. Saip P, Eralp M, Ozkan M, et al. Phase 2 study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer. ASCO Annual Meeting J Clin Oncol. 2011;29: (Suppl; abstr e13079).
36. Janni W, Sarosiek T, Papadimitrou C, et al. A phase 2 randomized trial of lapatinib with either vinorelbine or capecitabine as first-and second-line therapy for ErbB2-overexpressing Metastatic Breast Cancer (MBC): Safety results. ASCO Annual Meeting J Clin Oncol. 2011;29: (Suppl; abstr e11097).
37. Valero M, Ruiz-Borrego M, Salvador D, et al. Cisplatin, gencitabine, and lapatinib in patients with HER2-positive metastatic breast cancer: An experience in routine clinical practice. ASCO Annual Meeting J Clin Oncol. 2011;29:(Suppl; abstr e11005).
38. Untch M, Loibl S, Bischoff J, et al. Lapatinib vs. Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO STUDY (GBG 44). Proceedings of the SABCS. 2010;Abs [S3-1].
39. Park I, Lee K, Kang H, et al. A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2-positive early breast cancer. ASCO Annual Meeting J Clin Oncol. 2011;29:(Suppl; abstr e11069).
40. Bueno Hume C, Moreno-Aspitia A, Hillman D, et al. Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E. ASCO Annual Meeting J Clin Oncol. 2010;28:(Suppl; abstr 565).
41. Chu QS, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res. 2008;14(14):4484-90.
42. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. JCO. 2009;27(33): 5538-46.
43. Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. JCO. 2008;26(20):3317-23.
44. Wu Y, Amonkar MM, Sherrill BH, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011;22(12):2582-90.
45. Burstein HJ, Blackwell KL, Wu Y, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life (QOL) of patients with trastuzumab-refractory HER2+ (ErbB2+) metastatic breast cancer (MBC). Proceedings of the Breast Cancer. 2008;Symposium-Abstract 154.
46. Baselga J, Bradbury I, Eidtmann H, Cosimo S, C A. First results of the NeoALTTO trial (BIG 01-6/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2HER2-positive primary breast cancer Proceedings of the SABCS. 2010;Abs [S3-3].
47. Falchook G, Moulder S, Wheler J, et al. Combination trastuzumab, lapatinib, and bevacizumab in HER2+ breast cancer and other malignancies. ASCO Annual Meeting J Clin Oncol. 2009;27:(Suppl; abstr 244).
48. Hoban C, Hoering A, Synold T, et al. Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528. ASCO Annual Meeting J Clin Oncol. 2009;27: (Suppl; abstr 3553).
49. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. JCO. 2008;26(12):1993-9.
50. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-9.
51. Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2011;22(3):625-30.
52. Azambuja E, Lemort M, Rossari J, et al. Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). ASCO Annual Meeting J Clin Oncol. 2010;29:(suppl; abstr 570).
53. Lin NU, Younger W, et al. Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer. ASCO Annual Meeting J Clin Oncol. 2010;28:15s (suppl; abstr 1154).
54. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. JCO. 2010;28(8):1301-7.
55. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263-75.